Download PDF
Semin Neurol 2000; Volume 20(Number 03): 293-306
DOI: 10.1055/s-2000-9393
Copyright © 2000 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Acute Bacterial Meningitis

Karen L. Roos
  • Department of Neurology, Indiana University School of Medicine, Indianapolis, Indiana
Further Information

Publication History

Publication Date:
31 December 2000 (online)

    Permissions and Reprints

ABSTRACT

In the past 10 years the epidemiology of bacterial meningitis has changed, with a decreased incidence of meningitis caused by Haemophilus influenzae and an increasing incidence of meningitis caused by penicillin- and cephalosporin-resistant strains of Streptococcus pneumoniae. Meningococcal meningitis has become an increasing threat to college students. Successful outcome from meningitis requires not only eradication of the bacterial pathogen but also management of the neurological complications of raised intracranial pressure, stroke, and seizure activity. In this article, the pathophysiology, etiology, clinical presentation, differential diagnosis, and management of acute bacterial meningitis are reviewed. The present recommendations for the use of dexamethasone in the treatment of this infection, the use of chemoprophylaxis, and the indications for vaccinations are included.

KEYWORD

Bacterial meningitis - dexamethasone - vaccination

REFERENCES

  • 1 Vieusseux G. Mémoire sur la maladie qui a régne a Geneve au printemps de 1805.  J Med Chi Pharm . 1806;  11 163-182
    PubMedGoogle Scholar
  • 2 Danielson L, Mann E. The history of a singular and very mortal disease which lately made its appearance in Medfield. In: Adams B, ed. The Medical and Agricultural Register Boston: Manning and Loring 1806: 65-69
    Google Scholar
  • 3 Verghese A, Gallemore G. Kernig's and Brudzinski's signs revisited.  Rev Infect Dis . 1987;  9 1187-1192
    PubMedGoogle Scholar
  • 4 Quincke H. Uber hydrocephalus, Verhandlungen des Congressus fur innere Medizin. Vol 10. Wiesbaden: JF Bergman 1891: 321
    Google Scholar
  • 5 Macfarlane G. Alexander Fleming: The Man and the Myth. Oxford: Oxford University Press 1985: 117-127
    Google Scholar
  • 6 Scheld W M, Mandell G L. Sulfonamides and meningitis.  JAMA . 1984;  251 791-794
    CrossrefPubMedGoogle Scholar
  • 7 Schwentker F F, Gelman S, Long P H. The treatment of meningococcic meningitis with sulfanilamide.  JAMA . 1984;  251 788-790
    CrossrefPubMedGoogle Scholar
  • 8 Bell W E, Silber D L. Meningococcal meningitis: past and present concepts.  Mil Med . 1971;  136 601-611
    PubMedGoogle Scholar
  • 9 Rosenberg D H, Arling P A. Penicillin in the treatment of meningitis.  JAMA . 1944;  125 1011-1017
    PubMedGoogle Scholar
  • 10 Tauber M G, Sande M A. The impact of penicillin on the treatment of meningitis.  JAMA . 1984;  251 1877-1880
    CrossrefPubMedGoogle Scholar
  • 11 Simberkoff M S, Moldover N H, Rahal Jr J. Absence of detectable bactericidal and opsonic activities in normal and infected human cerebrospinal fluids: a regional host defense deficiency.  J Lab Clin Med . 1980;  95 362-367
    PubMedGoogle Scholar
  • 12 Tauber M G, Moser B. Cytokines and chemokines in meningeal inflammation: biology and clinical implications.  Clin Infect Dis . 1999;  28 1-12
    PubMedGoogle Scholar
  • 13 Pfister H W, Borasio G D, Dirnagl U, Bauer M, Einhaupl K M. Cerebrovascular complications of bacterial meningitis in adults.  Neurology . 1992;  42 1497-1504.
    CrossrefPubMedGoogle Scholar
  • 14 Feigin R D, McCracken G H, Klein J O. Diagnosis and management of meningitis.  Pediatr Infect Dis J . 1992;  11 785-814
    PubMedGoogle Scholar
  • 15 Hoban D J, Witwicki E, Hammond G W. Bacterial antigen detection in cerebrospinal fluid of patients with meningitis .  Diagn Microbiol Infect Dis . 1985;  3 373-379
    CrossrefPubMedGoogle Scholar
  • 16 Maxson S, Lewno M J, Schutze G E. Clinical usefulness of cerebrospinal fluid bacterial antigen studies.  J Pediatr . 1994;  125 235-238
    PubMedGoogle Scholar
  • 17 Dwelle T L, Dunkle L M, Blair L. Correlation of cerebrospinal fluid endotoxin-like activity with clinical and laboratory variables in gram-negative bacterial meningitis in children .  J Clin Microbiol . 1987;  25 856-858
    PubMedGoogle Scholar
  • 18 Fishman R A. CSF findings in diseases of the nervous system. In: Fishman RA, ed. Cerebrospinal Fluid in Diseases of the Nervous System Philadelphia: WB Saunders 1992: 253-343
    Google Scholar
  • 19 Durack D T, Spanos A. End-of-treatment spinal tap in bacterial meningitis: is it worthwhile? .  JAMA . 1982;  248 75-78
    CrossrefPubMedGoogle Scholar
  • 20 National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing Villanova, PA: National Committee for Laboratory Standards; 1994
  • 21 Sanders C C. Cefepime: the next generation?.  Clin Infect Dis . 1993;  17 369-379
    PubMedGoogle Scholar
  • 22 Saez-Llorens X, Castano E, Garcia R. Prospective randomized comparison of cefepime and cefotaxime for treatment of bacterial meningitis in infants and children.  Antimicrob Agents Chemother . 1995;  39 937-940
    PubMedGoogle Scholar
  • 23 Patel J B, Giles R E. Meropenem: Evidence of lack of proconvulsive tendency in mice.  J Antimicrob Chemother . 1989;  307-309 (307-309)
    PubMedGoogle Scholar
  • 24 Lepper M H, Spies H W. Treatment of pneumococcic meningitis.  AMA Arch Intern Med . 1959;  104 253-259
    PubMedGoogle Scholar
  • 25 Tauber M G, Khayam-Bashi H, Sande M. Effects of ampicillin and corticosteroids on brain water content, cerebrospinal fluid pressure, and cerebrospinal fluid lactate levels in experimental pneumococcal meningitis.  J Infect Dis . 1985;  151 528-534
    PubMedGoogle Scholar
  • 26 Lebel M H, Freij B, Syrogiannopoulos G A. Dexamethasone therapy for bacterial meningitis.  N Engl J Med . 1988;  319 964-971
    PubMedGoogle Scholar
  • 27 Lebel M H, Hoyt M J, Waagner D C, Rollins N K, Finitzo T, McCracken G H. Magnetic resonance imaging and dexamethasone therapy for bacterial meningitis .  Am J Dis Child . 1989;  143 301-306
    PubMedGoogle Scholar
  • 28 Girgis N I, Farid Z, Mikhail I A, Farrag I, Sultan Y, Kilpatrick M E. Dexamethasone treatment for bacterial meningitis in children and adults .  Pediatr Infect Dis J . 1989;  8 848-851
    PubMedGoogle Scholar
  • 29 Odio C M, Faingezicht I, Paris M. The beneficial effects of early dexamethasone administration in infants and children with bacterial meningitis.  N Engl J Med . 1991;  324 1525-1531
    PubMedGoogle Scholar
  • 30 Schaad U B, Lips U, Gnehm H E, Blumberg A, Heinzer I, Wedgewood J. Dexamethasone therapy for bacterial meningitis in children.  Lancet . 1993;  342 457-461
    CrossrefPubMedGoogle Scholar
  • 31 King S M, Law B, Langley J M. Dexamethasone therapy for bacterial meningitis: better never than late? .  Can J Infect Dis . 1994;  5 210-215
    PubMedGoogle Scholar
  • 32 Wald E R, Kaplan S L, Mason E O. Dexamethasone therapy for children with bacterial meningitis.  Pediatrics . 1995;  95 21-28
    PubMedGoogle Scholar
  • 33 Kilpi T, Peltola H, Jauhiainen T, Kallio M J. Oral glycerol and intravenous dexamethasone in preventing neurologic and audiologic sequelae of childhood bacterial meningitis.  Pediatr Infect Dis J . 1995;  14 270-278
    PubMedGoogle Scholar
  • 34 Ciana G, Antonio C, Pivetta S, Tamburlini G, Cuttini M. Effectiveness of adjunctive treatment with steroids in reducing short-term mortality in a high-risk population of children with bacterial meningitis .  J Trop Pediatr . 1995;  41 164-168
    PubMedGoogle Scholar
  • 35 Kanra G Y, Ozen H, Secmeer G, Ceyhan M, Ecevit Z, Belgin E. Beneficial effects of dexamethasone in children with pneumococcal meningitis .  Pediatr Infect Dis J . 1995;  14 490-494
    PubMedGoogle Scholar
  • 36 Qazi S, Khan M A, Mughal N. Dexamethasone and bacterial meningitis in Pakistan.  Arch Dis Child . 1996;  75 482-488
    CrossrefPubMedGoogle Scholar
  • 37 McIntyre P B, Berkey C S, King S M. Dexamethasone as adjunctive therapy in bacterial meningitis.  JAMA . 1997;  278 925-931
    CrossrefPubMedGoogle Scholar
  • 38 Paris M M, Hickey S M, Uscher M I, Shelton S, Olsen K D, McCracken G H. Effect of dexamethasone on therapy of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis.  Antimicrob Agents Chemother . 1994;  38 1320-1324
    CrossrefPubMedGoogle Scholar
  • 39 Cabellos C, Martinez-Lacasa J, Martos A. Influence of dexamethasone on efficacy of ceftriaxone and vancomycin therapy in experimental pneumococcal meningitis.  Antimicrob Agents Chemother . 1995;  39 2158-2160
    PubMedGoogle Scholar
  • 40 Klugman K P, Friedland I R, Bradley J S. Bactericidal activity against cephalosporin-resistant Streptococcus pneumoniae in cerebrospinal fluid of children with acute bacterial meningitis.  Antimicrob Agents Chemother . 1995;  39 1988-1992
    PubMedGoogle Scholar
  • 41 Viladrich P F, Gudiol F, Linares J. Evaluation of vancomycin for therapy of adult pneumococcal meningitis .  Antimicrob Agents Chemother . 1991;  35 2467-2472
    PubMedGoogle Scholar
  • 42 Harrison L H, Dwyer D M, Maples C T, Billmann L. Risk of meningococcal infection in college students.  JAMA . 1999;  281 1906-1909
    CrossrefPubMedGoogle Scholar
  • 43 Peltola H. Prophylaxis of bacterial meningitis.  Infect Dis Clin North Am . 1999;  13 685-706
    CrossrefPubMedGoogle Scholar
      >